Amelioration of mitochondrial dysfunction-induced insulin resistance in differentiated 3T3-L1 adipocytes via inhibition of NF-κB pathways

Int J Mol Sci. 2014 Dec 2;15(12):22227-57. doi: 10.3390/ijms151222227.

Abstract

A growing body of evidence suggests that activation of nuclear factor kappa B (NF-κB) signaling pathways is among the inflammatory mechanism involved in the development of insulin resistance and chronic low-grade inflammation in adipose tissues derived from obese animal and human subjects. Nevertheless, little is known about the roles of NF-κB pathways in regulating mitochondrial function of the adipose tissues. In the present study, we sought to investigate the direct effects of celastrol (potent NF-κB inhibitor) upon mitochondrial dysfunction-induced insulin resistance in 3T3-L1 adipocytes. Celastrol ameliorates mitochondrial dysfunction by altering mitochondrial fusion and fission in adipocytes. The levels of oxidative DNA damage, protein carbonylation and lipid peroxidation were down-regulated. Further, the morphology and quantification of intracellular lipid droplets revealed the decrease of intracellular lipid accumulation with reduced lipolysis. Moreover, massive production of the pro-inflammatory mediators tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) were markedly depleted. Insulin-stimulated glucose uptake activity was restored with the enhancement of insulin signaling pathways. This study signified that the treatments modulated towards knockdown of NF-κB transcription factor may counteract these metabolic insults exacerbated in our model of synergy between mitochondrial dysfunction and inflammation. These results demonstrate for the first time that NF-κB inhibition modulates mitochondrial dysfunction induced insulin resistance in 3T3-L1 adipocytes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3T3-L1 Cells
  • Adipocytes / cytology*
  • Adipocytes / drug effects
  • Adipocytes / metabolism*
  • Animals
  • Cell Differentiation* / drug effects
  • Cell Survival / drug effects
  • Electron Transport / drug effects
  • Glucose / metabolism
  • Glucose Transporter Type 1 / metabolism
  • Glucose Transporter Type 4 / metabolism
  • Humans
  • Insulin / pharmacology
  • Insulin Resistance*
  • Interleukin-1beta / biosynthesis
  • Intracellular Space / drug effects
  • Intracellular Space / metabolism
  • Lipolysis / drug effects
  • Mice
  • Mitochondria / drug effects
  • Mitochondria / metabolism
  • Mitochondria / pathology*
  • NF-kappa B / metabolism*
  • Oligomycins / chemistry
  • Oligomycins / pharmacology
  • Oxidative Stress / drug effects
  • Pentacyclic Triterpenes
  • Signal Transduction* / drug effects
  • Triterpenes / chemistry
  • Triterpenes / pharmacology
  • Tumor Necrosis Factor-alpha / biosynthesis

Substances

  • Glucose Transporter Type 1
  • Glucose Transporter Type 4
  • Insulin
  • Interleukin-1beta
  • NF-kappa B
  • Oligomycins
  • Pentacyclic Triterpenes
  • Triterpenes
  • Tumor Necrosis Factor-alpha
  • Glucose
  • celastrol